Ovarian cancer ranks among the most frightening female reproductive system malignancies worldwide, striking thousands of women every year and delivering a devastating blow to patients and their families. Unlike breast or cervical cancer, ovarian cancer often hides in plain sight; early symptoms are vague bloating, mild pelvic discomfort, and fatigue that most people brush off as ordinary digestive upset or stress. By the time persistent pain, rapid weight loss, or enlarged abdominal fluid sends patients for imaging tests, roughly 70% to 80% of ovarian tumors have already spread beyond the ovaries. Even after aggressive surgery to remove all visible tumor tissue and full rounds of platinum-based chemotherapy—the standard first-line treatment for decades—most patients will face an inevitable recurrence.
For decades, doctors have sorted recurrent ovarian cancer into two critical groups based on the platinum-free interval (PFI), the length of time patients stay cancer-free after finishing platinum chemo. If tumors grow back within six months of platinum therapy, patients receive a grim diagnosis: platinum-resistant recurrent ovarian cancer (PROC). This subgroup faces the worst prognosis of all ovarian cancer patients, with extremely limited effective treatment choices. Traditional non-platinum single-agent chemotherapy barely shrinks tumors in fewer than 20% of patients, keeps cancer at bay for less than four months on average, and extends overall survival to barely one year. Worse, these chemo drugs trigger harsh side effects—severe nausea, hair loss, low blood cell counts, and chronic fatigue—that crush daily quality of life. Millions of women with PROC wait desperately for safer, more powerful drug combinations that can shrink tumors longer and let them live more comfortably.
This article breaks down a groundbreaking clinical trial out of Central South University’s Second Xiangya Hospital in Changsha, China (trial ID ). The study tests a two-drug pairing: disitamab vedotin, also known as RC48, a targeted antibody-drug conjugate (ADC), paired with anlotinib hydrochloride, an oral anti-angiogenesis pill. The trial targets women with HER2-expressing platinum-resistant recurrent ovarian cancer, exploring whether this dual-target approach can beat the limitations of old chemo regimens. We will walk through the basics of ovarian cancer recurrence, explain how each medication works in simple terms, cover the core logic behind combining them, and outline what this early-phase trial could mean for patients stuck with limited treatment options. This piece is written for patients, family caregivers, and general readers with no medical background—no confusing jargon left unexplained.
The Heavy Burden of Platinum-Resistant Recurrent Ovarian Cancer
To understand why this new trial matters, we first need to unpack exactly what makes platinum-resistant ovarian cancer such a tough medical challenge.
Ovarian cancer covers three related cancer types tracked together in clinical care: epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. These tumors share similar growth patterns, treatment pathways, and recurrence risks, and all respond initially to platinum chemotherapy drugs like carboplatin or cisplatin. Platinum chemo damages cancer cell DNA to stop rapid tumor division, but cancer cells evolve resistance over time. Once tumors return less than six months after platinum treatment ends, platinum drugs stop working reliably. At this stage, doctors cannot fall back on repeat platinum infusions; they must switch to non-platinum single chemo agents, which carry severe limitations.
Clinical data paints a bleak picture for PROC patients receiving standard single-agent chemotherapy:
- Objective response rate (ORR, the percentage of patients whose tumors shrink significantly or vanish entirely): Less than 20%
- Median progression-free survival (PFS, time before tumors start growing again): Fewer than four months
- Median overall survival (OS, total time patients live after recurrence): Under 12 months
- Severe, life-disrupting side effects that erode daily quality of life
Beyond poor treatment outcomes, PROC disproportionately impacts women’s mental health. Many patients face repeated rounds of exhausting treatment, constant scans to monitor tumor growth, and fear of running out of viable therapies. The medical community has long identified a critical unmet clinical need: new treatment regimens that deliver higher tumor shrinkage rates, longer cancer control, milder side effects, and better quality of life for platinum-resistant ovarian cancer patients.
One key biological marker has emerged to guide smarter targeted therapy for ovarian tumors: HER2, short for human epidermal growth factor receptor 2. HER2 is a protein that sits on the outer surface of many cancer cells, acting like a growth switch that fuels rapid tumor multiplication. Research consistently links HER2 expression in ovarian cancer to poorer patient outcomes. Tumors with detectable HER2 protein grow faster, spread more easily, and resist standard chemotherapy more readily than HER2-negative tumors. However, HER2 also creates a unique therapeutic opening: drugs can be engineered to lock onto this protein and destroy HER2-positive cancer cells without overwhelming healthy tissue. This targeting strategy forms the backbone of disitamab vedotin (RC48), the first drug in this trial’s combination.
Meet the Two Star Treatments of the Trial: RC48 and Anlotinib
This clinical trial combines two entirely distinct classes of anti-cancer medications that attack ovarian tumors through separate, complementary mechanisms. Neither drug relies on broad, toxic chemotherapy cell killing, and their side effect profiles do not heavily overlap—meaning patients face fewer cumulative severe adverse reactions compared to stacked chemo regimens. Below is a plain-language breakdown of each drug, their individual track records, and why they pair so well together.
Disitamab Vedotin (RC48): The Precision “Smart Bomb” Antibody-Drug Conjugate (ADC)
If standard chemotherapy is a blunt grenade that hits every fast-dividing cell (hair, gut lining, bone marrow alongside cancer), antibody-drug conjugates (ADCs) act as guided missiles. Each ADC molecule has three core parts: a targeting antibody that latches onto a unique protein on cancer cells, a tiny toxic chemotherapy payload, and a chemical linker that keeps the payload inactive until the ADC enters a tumor cell.
RC48 (disitamab vedotin) is a novel HER2-targeted ADC, awarded the U.S. FDA’s Breakthrough Therapy Designation back in April 2020—a special status reserved for drugs that show massive potential to treat serious diseases with limited existing options. Its antibody segment specifically binds to HER2 proteins on tumor cell surfaces. Once attached, the cancer cell swallows the entire ADC molecule, the linker breaks apart inside the cell, and the toxic payload releases to kill the tumor cell from within. Healthy cells without HER2 protein receive almost no damage, drastically cutting down on the widespread side effects of traditional chemo.
Preclinical lab studies using ovarian cancer cell lines confirmed RC48 delivers powerful targeted cell death to HER2-expressing ovarian tumors. Real-world clinical trial data from gynecologic cancer patients, presented at the 2024 European Congress of Gynecological Oncology (ESGO), further validated RC48’s value: in patients with recurrent or metastatic cervical cancer, single-agent RC48 achieved an objective response rate of 36.4%, a median progression-free survival of 4.37 months, and a one-year overall survival rate of 66%. Most treatment-related side effects landed at mild Grade 1 or moderate Grade 2 severity, and all symptoms fully resolved with simple supportive care. These results stood head and shoulders above older chemotherapy options for gynecologic cancers, with far less debilitating toxicity.
For this trial, RC48 is administered via slow intravenous (IV) infusion into a vein at a fixed dose of 2.0 mg per kilogram of body weight, given once every two weeks on Day 1 of each treatment cycle. The IV delivery ensures the drug circulates through the bloodstream to reach distant metastatic ovarian tumor sites across the abdomen and pelvis.
Anlotinib Hydrochloride: The Oral Anti-Angiogenesis Pill That Cuts Tumors’ Blood Supply
Tumors cannot grow larger than a tiny grain of sand without new blood vessels feeding them oxygen and nutrients—a biological process called angiogenesis. Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI), a daily pill that blocks multiple key signaling proteins that tumors use to build new blood vessels. By cutting off a tumor’s blood supply, anlotinib starves cancer lesions, halts their expansion, and can shrink existing metastatic growths. Unlike IV chemo or ADCs, patients take anlotinib at home as an oral capsule, eliminating repeated hospital infusion visits.
Single-agent anlotinib has already proven meaningful activity against platinum-resistant ovarian cancer in prior clinical testing, with impressive results compared to standard chemo:
- Objective response rate (ORR): 31.2%
- Median progression-free survival (PFS): 5.3 months
- 12-month overall survival rate: 90.9%
Similar to RC48, most side effects from anlotinib fall into mild Grade 1 or moderate Grade 2 categories, making it far more tolerable than traditional chemotherapy regimens. The trial uses a standard intermittent dosing schedule for anlotinib: patients take 10 mg by mouth once daily before meals for two full weeks, then pause the drug for one week. This 2-weeks-on, 1-week-off cycle balances maximum anti-tumor effect with time for the body’s healthy tissue to recover from mild drug-related stress. Each full combined treatment cycle (RC48 infusions plus anlotinib pills) lasts 21 days total.
Why Combining RC48 and Anlotinib Makes Scientific Sense
The trial’s core innovation lies in pairing these two drugs to create a synergistic anti-tumor effect—meaning the two medicines work better together than either could alone, with minimal overlapping toxicity. Multiple preclinical and early clinical studies have proven ADCs paired with anti-angiogenesis TKIs create mutually beneficial tumor suppression:
- Anlotinib’s blood vessel blocking action loosens the dense, scar-like tissue surrounding ovarian tumors. This improves blood flow penetration into tumor lesions, allowing more RC48 ADC molecules to reach and bind HER2-positive cancer cells deep inside tumors that previously remained unreachable by targeted therapy.
- The two drugs attack tumors through completely separate biological pathways: RC48 directly kills HER2-expressing cancer cells from the inside, while anlotinib starves tumors by blocking new blood vessel formation. Cancer cells cannot easily develop simultaneous resistance to two entirely distinct attack methods, delaying tumor progression longer than single-drug therapy.
- Their side effect profiles rarely overlap. RC48’s most common mild adverse events center on low white blood cell counts and mild nerve tingling, while anlotinib’s typical mild symptoms include mild high blood pressure and fatigue. The two drugs do not amplify severe toxicities when combined, keeping treatment tolerable for long-term use.
- Early combination testing of RC48 plus anlotinib in other solid tumor types has generated promising safety signals, laying groundwork to expand this combination into hard-to-treat ovarian cancer populations.
For women with HER2-expressing platinum-resistant ovarian cancer, this pairing targets both the cancer cells themselves and the tumor’s supporting blood vessel network simultaneously—an approach single-agent chemotherapy or single targeted drugs cannot match.
Overview of the Clinical Trial: Core Design, Goals, and Patient Eligibility
This exploratory early-phase clinical trial (classified as Early Phase 1) launched in October 2024 at the Second Xiangya Hospital of Central South University in Changsha, China, led by principal investigator Dr. Jingjing Wang, Associate Chief Physician of the gynecologic oncology department. The trial remains actively recruiting eligible female patients as of 2026, with an estimated target enrollment of 5 participants for this single-group exploratory study. Unlike large randomized trials that split patients into separate treatment and control groups, every participant in this trial receives the identical RC48 plus anlotinib combination therapy, allowing researchers to quickly collect initial safety and efficacy data for this new ovarian cancer regimen.
Clinical trials separate outcome measurements into primary endpoints (the single most important result researchers want to measure) and secondary endpoints (additional supporting data to judge treatment value). All patient tumor and survival assessments will continue for up to two years starting from the first treatment dose.
- Primary Endpoint: Objective Response Rate (ORR)
The main question the trial aims to answer: What percentage of participants experience measurable tumor shrinkage? Using standard global cancer assessment rules called RECIST 1.1, researchers classify each patient’s best tumor response as complete response (CR, all visible tumors disappear entirely) or partial response (PR, tumors shrink by at least 30%). ORR calculates the share of patients who hit either CR or PR—this number directly shows how well the combination shrinks platinum-resistant ovarian tumors. - Key Secondary Endpoints
- Progression-Free Survival (PFS): The length of time from starting treatment until tumors begin growing again, or until the patient passes away (whichever comes first). Longer PFS means the treatment holds cancer at bay for more time without disease worsening.
- Overall Survival (OS): Total time each patient lives after enrolling in the trial, tracking long-term survival benefits of the dual-drug regimen.
- Disease Control Rate (DCR): The percentage of patients with shrinking tumors (CR/PR) OR stable disease (SD, tumors do not grow or shrink significantly). DCR captures how many patients see any form of cancer control from the treatment.
- Duration of Response (DoR): How long tumor shrinkage lasts for patients who experience CR or PR, measuring how durable the treatment’s anti-tumor effect remains. Trial Timeline Basics
The trial launched with an estimated start date of October 15, 2024, with planned primary data collection completion in September 2025 and full study wrap-up in mid-October 2025. At publication, the trial remains actively recruiting patients at the Second Xiangya Hospital in Changsha, Hunan Province, China. Patients interested in learning more can contact lead investigator Dr. Jingjing Wang via the provided phone and email listed on the U.S. National Clinical Trials database entry . What This Trial Means for Ovarian Cancer Patients Around the World
This small exploratory early-phase trial carries outsized importance for global ovarian cancer care, for three central reasons:
First, it addresses a massive unmet clinical gap for platinum-resistant recurrent ovarian cancer, a patient population stuck with ineffective, poorly tolerated chemotherapy as standard care. If the RC48 + anlotinib combination delivers higher tumor shrinkage rates and longer cancer control with mild side effects, this dual-target regimen could become a new standard second-line treatment for HER2-expressing PROC patients worldwide. Unlike older chemo, the pairing combines an IV targeted ADC with an oral home-administered TKI pill, balancing hospital-based infusions with convenient at-home daily medication to reduce patient burden.
Second, the trial uses HER2 biomarker testing to deliver personalized targeted therapy. For decades, ovarian cancer treatment relied on one-size-fits-all platinum chemo regardless of individual tumor biology. This study builds on a growing global shift toward precision oncology: testing patient tumor tissue for molecular markers like HER2 to match patients to therapies most likely to work for their unique cancer subtype. As more trials validate HER2 as a treatment target in ovarian cancer, routine HER2 testing may become standard practice for all recurrent ovarian cancer patients in oncology clinics globally.
Third, the trial establishes a replicable combination framework for ADC plus anti-angiogenesis TKI therapy across multiple solid tumors. Positive safety and efficacy data from this ovarian cancer trial will encourage researchers to launch larger, multi-center randomized trials with far more participants, to confirm whether RC48 plus anlotinib delivers consistent survival benefits for PROC patients. Successful early-phase results could also inspire testing of similar ADC-TKI pairings for other hard-to-treat HER2-positive cancers, including gastric, lung, and biliary tract malignancies.
Crucially, this research originates from a Chinese academic hospital, expanding global diversity in clinical trial research for gynecologic cancers. Most historic ovarian cancer drug trials originated from Western research centers; trials conducted in Asian patient populations help doctors understand how targeted therapies perform across different ethnic groups, ensuring treatment guidelines reflect diverse patient biology worldwide.
Limitations and Realistic Patient Expectations
While the trial represents exciting medical progress, it is vital for readers to maintain realistic expectations of early exploratory clinical research. This study is small, with a planned enrollment of only five participants, designed primarily to test safety and gather preliminary efficacy signals rather than generate definitive, universally applicable treatment data. Early Phase 1 trials exist to answer basic questions: Is this drug combination safe to give to patients? Do we see any signs of tumor shrinkage that justify larger follow-up trials? Positive preliminary results from this small group will not immediately lead to widespread global drug approval; years of larger randomized clinical trials will be required to confirm consistent survival benefits before regulators like the FDA or China’s NMPA can approve RC48 plus anlotinib as standard clinical therapy.
Additionally, this regimen only applies to ovarian cancer patients whose tumors show detectable HER2 protein expression (IHC 1+, 2+, or 3+). Patients with fully HER2-negative tumors will not benefit from RC48’s targeted HER2 binding mechanism, so this combination cannot serve as a universal treatment for all platinum-resistant ovarian cancer patients. Tumor tissue testing remains a mandatory first step to identify eligible candidates for this therapy.
All clinical trials carry small inherent risks of unexpected side effects, even when preclinical lab data predicts mild toxicity. Researchers will closely monitor all trial participants for blood pressure changes, bleeding risk, low blood cell counts, nerve discomfort, and other potential adverse events throughout the two-year assessment window, pausing or adjusting treatment doses immediately if severe toxicity emerges to protect patient safety.
Conclusion
For women living with recurrent platinum-resistant ovarian cancer, every new clinical trial exploring safer, more effective treatment options represents a vital glimmer of hope. The trial out of Central South University’s Second Xiangya Hospital tests a novel dual-target combination of disitamab vedotin (RC48) and anlotinib hydrochloride, pairing a precision HER2 antibody-drug conjugate with an oral anti-angiogenesis pill to attack ovarian tumors on two separate biological fronts.
Standard single-agent chemotherapy leaves PROC patients with low tumor response rates, short cancer-free intervals, harsh side effects, and limited survival. RC48 and anlotinib each deliver meaningful anti-tumor activity as standalone therapies with mild tolerable toxicity, and their complementary mechanisms create synergistic tumor suppression when combined. This early exploratory trial aims to collect initial safety and efficacy data to determine whether this dual-drug regimen can boost tumor shrinkage, extend cancer control, and improve quality of life for HER2-expressing platinum-resistant ovarian cancer patients.
While this small early-phase study cannot deliver final treatment answers, it opens a promising new chapter in personalized ovarian cancer treatment. If the trial generates encouraging results, larger multi-center trials will follow to validate these findings, potentially introducing a transformative new targeted therapy combination for thousands of women facing the devastating diagnosis of platinum-resistant recurrent ovarian cancer. For patients, caregivers, and oncologists alike, this research underscores the power of precision oncology: matching targeted drugs to individual tumor molecular markers to replace outdated, toxic blanket chemotherapy with smarter, gentler, more effective cancer care.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
A Study Comparing BL-B01D1 With the Investigator’s Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTrial of THEO-260 in Ovarian Cancer Patients
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSurvivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
This study will enroll 120 women living with ovarian cancer following completion of initial treatment. Our objective is to test an intervention designed to provide support during the survivorship transition for this population, who live with a high degree of morbidity related to the illness and its treatment as well as a high risk of recurrence. Study participants will be randomly assigned to receive survivorship care using the POSTCare-O process or usual care. The primary outcome is quality of life at 12 weeks after intervention.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoThe FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll in the study, they will: * Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days. * Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRC48 in Combination With AK104 and Bevacizumab in OCCC
Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoDrug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoLetrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor positive low-grade serous epithelial carcinoma of the ovary (LGSCO). The hypothesis is that letrozole will significantly prolong median progression free survival (PFS) compared with the standard chemotherapy treatment, namely carboplatin AUC 5 and paclitaxel 175 mg/m2.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAutophagy Maintenance (AUTOMAIN)
This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of Azenosertib (ZN-c3) Versus Investigator’s Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator’s choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. * Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. Exploratory analysis of the association between the efficacy of the combination regimen and biomarkers.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEvaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction
This study is being carried out to better understand how different types of mastectomy surgeries affect women’s recovery, satisfaction, and overall well-being after breast cancer surgery and reconstruction. There are different ways to perform a mastectomy. In some patients, a nipple-sparing mastectomy may be suitable, where the nipple and surrounding breast skin are preserved. This approach allows for immediate breast reconstruction with an implant, which is placed at the same time as the mastectomy to restore the breast shape. A newer technique called robotic single-port nipple-sparing mastectomy uses advanced robotic technology to remove breast tissue through a small hidden incision at the side of the chest. This method may reduce scarring, pain, and recovery time, while preserving the appearance and sensation of the breast. However, while early studies suggest this technique is safe and effective, more evidence is needed to compare it directly with standard surgeries. This study will compare: * Robotic nipple-sparing mastectomy * Standard (open) nipple-sparing mastectomy We will assess patient satisfaction, body image, physical and emotional well-being, and surgical outcomes over 12 months following surgery. By taking part, you are helping researchers evaluate whether robotic and nipple-sparing approaches offer measurable benefits to patients. Taking part in this study will not affect your surgery or the care you receive. You will be given the best treatment available based on your individual medical needs, whether or not you decide to participate in the research.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEffect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoACT-Based Nursing Intervention for Ovarian Cancer Patients: A Pilot Study
The purpose of this study is to evaluate the feasiblity and effectiveness of an Acceptance and Commitment Therapy (ACT)-based nursing intervention aimed at managing psychological flexibility, distress, anxiety, depression, fear of cancer recurrence/progression, quality of life, and symptoms. Patients will participate in a single online session with a nurse, followed by a daily self-monitoring survey online for one week. Data will be collected at baseline (prior to the ACT session), on day 8 (after one week of self-monitoring), and at 5 weeks. Primary outcome is psychological flexibility.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoJSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator’s choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for patients. TUB-040 is given IV every 3 weeks until the disease progresses or the patient has to stop due to side effects.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer. Target population will be patients (woman, age \> 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info